ClinicalTrials.gg

Program

GS 101

Also written as “GS101 injection” and “aganirsen”.

Its studies are mostly in Dermatitis, Atopic · Glaucoma, Neovascular, led by 2 companies.

Furthest: phase 3, since Jan 26, 20263 company-led studies, 1 open or runningNext primary completion: Apr 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu Genscend Biopharmaceutical21 open or runningphase 3since Jan 26, 2026Jan 26, 2026Apr 2027phase 3 · NCT07386743
Gene Signal SAS10 open or runningphase 3since Oct 15, 2016Oct 15, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 15, 2016First study: phase 3 study in Glaucoma, NeovascularNew to Gene Signal SASGene Signal SAS · NCT02947867 · 333 enrolled
  2. Jan 26, 2026Jiangsu Genscend Biopharmaceutical's first study: phase 3 study in Dermatitis, AtopicNew to Jiangsu Genscend BiopharmaceuticalJiangsu Genscend Biopharmaceutical · NCT07386743 · 572 planned · China
  3. Feb 9, 2026Phase 1 study in Dermatitis, AtopicJiangsu Genscend Biopharmaceutical · NCT07411755 · 294 enrolled · China

Ahead

  1. Apr 2027Primary completion: phase 3 study in Dermatitis, AtopicJiangsu Genscend Biopharmaceutical · NCT07386743

TargetBeta

IRS1 →read by rule
“A 25-mer antisense oligonucleotide (ASO) that targets the mRNA transcript for insulin receptor substrate (IRS-1), a protein required for the formation and growth of new blood vessels, that can be used to reduce corneal angiogenesis and neovascularization”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07411755Dermatitis, Atopic · China1CompletedJiangsu Genscend BiopharmaceuticalAug 8, 2026294
NCT07386743Dermatitis, Atopic · China3RecruitingJiangsu Genscend BiopharmaceuticalApr 2027572
NCT02947867Glaucoma, Neovascular3UNKNOWNGene Signal SASJun 2019333

How it is read

Names in the registry

  • “GS101 injection”, 2 entries
  • “aganirsen”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.